EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis

Wolfgang C Winkelmayer, Anthonie W A Lensing, Ravi I Thadhani, Kenneth W Mahaffey, Michael Walsh, Ákos F Pap, Stefan Willmann, Kirstin Thelen, Sophie Hodge, Alexander Solms, Sheila J M Ingham, John Eikelboom und 1 weitere

Kidney International · 2024-07 · 106 (1) · 145-153

DOI: 10.1016/j.kint.2024.02.024 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Kidney International, 2024-07. Verfasst von Wolfgang C Winkelmayer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: winkelma@bcm.edu. Hauptthemen laut MEDLINE: Renal Dialysis, Factor XI, Fibrinolytic Agents, Hemorrhage. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Bayer Pharma AG, McMaster University, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisFactor XIFibrinolytic AgentsHemorrhageThrombosisHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodTreatment OutcomeOligonucleotidesKidney Failure, ChronicDose-Response Relationship, Drug

Stichwörter der Autor:innen

end-stage kidney diseasefesomersenhemodialysisrandomized trial

Substanzen

Factor XIFibrinolytic AgentsOligonucleotides

Autor:innen und Institutionen

  • Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: winkelma@bcm.edu.
  • Clinical Development, Bayer AG, Wuppertal, Germany.
  • Woodruff Health Sciences Center, Emory School of Medicine, Atlanta, Georgia, USA.
  • Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University,…
  • Clinical Statistics, Bayer AG, Wuppertal, Germany.

Förderung

  • Bayer Pharma AG
  • McMaster University
  • Bayer
  • Bayer Fund

Zitieren

APA

Winkelmayer, W. C., Lensing, A. W. A., Thadhani, R. I., Mahaffey, K. W., Walsh, M., Pap, Á. F., Willmann, S., Thelen, K., Hodge, S., Solms, A., Ingham, S. J. M., Eikelboom, J., & RE-THINC investigators (2024). A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International, 106(1), 145-153. https://doi.org/10.1016/j.kint.2024.02.024

Vancouver

Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap ÁF, et al. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International. 2024;106(1):145-153. doi:10.1016/j.kint.2024.02.024

BibTeX
@article{Winkelmayer2024,
  author = {Winkelmayer, Wolfgang C and Lensing, Anthonie W A and Thadhani, Ravi I and Mahaffey, Kenneth W and Walsh, Michael and Pap, Ákos F and Willmann, Stefan and Thelen, Kirstin and Hodge, Sophie and Solms, Alexander and Ingham, Sheila J M and Eikelboom, John and RE-THINC investigators, RE-THINC investigators},
  title = {A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis},
  journal = {Kidney International},
  year = {2024},
  volume = {106},
  number = {1},
  pages = {145--153},
  doi = {10.1016/j.kint.2024.02.024}
}
Kostenlos starten →